Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Conditions:   Colorectal Cancer Metastatic;   Myelosuppression Adult;   Chemotherapeutic Toxicity Interventions:   Drug: Trilaciclib;   Drug: Placebo Sponsor:   G1 Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials